Photosensitizers in prostate cancer therapy

Taher Gheewala; Troy Skwor; Gnanasekar Munirathinam

doi:10.18632/oncotarget.15496

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Photosensitizers in prostate cancer therapy

Taher Gheewala, Troy Skwor and Gnanasekar Munirathinam _

PDF | HTML | How to cite

Oncotarget. 2017; 8:30524-30538. https://doi.org/10.18632/oncotarget.15496

Metrics: PDF 3501 views | HTML 5853 views | ?

Abstract

Taher Gheewala1, Troy Skwor2 and Gnanasekar Munirathinam1

1 Department of Biomedical Sciences, University of Illinois, College of Medicine, Rockford, IL, USA

2 Department of Chemical and Biological Sciences, Rockford University, Rockford, IL, USA

Correspondence to:

Gnanasekar Munirathinam, email:

Keywords: prostate cancer, photodynamic therapy, photosensitizers

Received: October 29, 2016 Accepted: February 06, 2017 Published: February 18, 2017

Abstract

The search for new therapeutics for the treatment of prostate cancer is ongoing with a focus on the balance between the harms and benefits of treatment. New therapies are being constantly developed to offer treatments similar to radical therapies, with limited side effects. Photodynamic therapy (PDT) is a promising strategy in delivering focal treatment in primary as well as post radiotherapy prostate cancer. PDT involves activation of a photosensitizer (PS) by appropriate wavelength of light, generating transient levels of reactive oxygen species (ROS). Several photosensitizers have been developed with a focus on treating prostate cancer like mTHPC, motexafin lutetium, padoporfin and so on. This article will review newly developed photosensitizers under clinical trials for the treatment of prostate cancer, along with the potential advantages and disadvantages in delivering focal therapy.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 15496

Publication Alerts

Post-Publication Promotion

Publication Discount

Reviews:

Photosensitizers in prostate cancer therapy

Abstract